CSL and Eli Lilly have entered into a licensing agreement on the development and commercialisation of clazakizumab, an interleukin-6 (IL-6) inhibitor monoclonal antibody.
CSL will retain exclusive rights of the drug for preventing cardiovascular events in patients with end-stage kidney disease (ESKD), while Lilly will pursue development, regulatory approvals and commercialisation for other conditions.
"This agreement marks a significant step forward in our mission to bring innovative therapies to patients worldwide," said Bill Mezzanotte, CSL EVP and head of research and development.
"Clazakizumub is a promising therapeutic candidate with the potential to significantly impact the treatment landscape for various immuno-inflammatory and cardiovascular conditions," he explained.
Having acquired the drug from its developer Vitaeris in 2020, CSL will now receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory and commercial milestone payments, as well as royalties on global sales.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Feb 26
